Literature DB >> 25982860

IFNA2: The prototypic human alpha interferon.

Franciane Paul1, Sandra Pellegrini2, Gilles Uzé3.   

Abstract

The human interferon α2 (IFNα2) was the first highly active IFN subtype to be cloned in the early eighties. It was also the first IFN and the first cytokine to be produced and commercialized by the pharmaceutical industry. Ipso facto it became the favorite IFNα subtype for academic researchers. For this fortunate reason IFNα2 has been at the origin of most discoveries related to the mechanism of action of type I interferons.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokine; Interferon α2; Type I interferon

Mesh：

Substances：

Year:  2015        PMID： 25982860      PMCID： PMC5629289          DOI： 10.1016/j.gene.2015.04.087

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  75 in total

1.  The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding.

Authors:  Jordan H Chill; Sabine R Quadt; Rina Levy; Gideon Schreiber; Jacob Anglister
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

2.  Three human interferon-alpha 2 subvariants disclose structural and functional differences.

Authors:  A von Gabain; E Lundgren; M Ohlsson; E Holmgren; S Josephsson; S S Alkan
Journal:  Eur J Biochem       Date:  1990-06-20

3.  High efficiency cell-specific targeting of cytokine activity.

Authors:  Geneviève Garcin; Franciane Paul; Markus Staufenbiel; Yann Bordat; José Van der Heyden; Stephan Wilmes; Guillaume Cartron; Florence Apparailly; Stefaan De Koker; Jacob Piehler; Jan Tavernier; Gilles Uzé
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

4.  The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.

Authors:  Eyal Kalie; Diego A Jaitin; Yulia Podoplelova; Jacob Piehler; Gideon Schreiber
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

5.  Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography.

Authors:  R Radhakrishnan; L J Walter; A Hruza; P Reichert; P P Trotta; T L Nagabhushan; M R Walter
Journal:  Structure       Date:  1996-12-15       Impact factor: 5.006

Review 6.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

7.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

Review 9.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

10.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation.

Authors:  Xianqin Zhang; Dusan Bogunovic; Béatrice Payelle-Brogard; Véronique Francois-Newton; Scott D Speer; Chao Yuan; Stefano Volpi; Zhi Li; Ozden Sanal; Davood Mansouri; Ilhan Tezcan; Gillian I Rice; Chunyuan Chen; Nahal Mansouri; Seyed Alireza Mahdaviani; Yuval Itan; Bertrand Boisson; Satoshi Okada; Lu Zeng; Xing Wang; Hui Jiang; Wenqiang Liu; Tiantian Han; Delin Liu; Tao Ma; Bo Wang; Mugen Liu; Jing-Yu Liu; Qing K Wang; Dilek Yalnizoglu; Lilliana Radoshevich; Gilles Uzé; Philippe Gros; Flore Rozenberg; Shen-Ying Zhang; Emmanuelle Jouanguy; Jacinta Bustamante; Adolfo García-Sastre; Laurent Abel; Pierre Lebon; Luigi D Notarangelo; Yanick J Crow; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Sandra Pellegrini
Journal:  Nature       Date:  2014-10-12       Impact factor: 49.962
View more
  23 in total

1.  Nasal Wash Cytokines during Respiratory Viral Infection in Pediatric Allogeneic Hematopoietic Cell-Transplant Recipients.

Authors:  Tim Flerlage; Aisha Souquette; E Kaitlynn Allen; Timothy Brahm; Jeremy Chase Crawford; Li Tang; Yilun Sun; Gabriela Maron; Joshua Wolf; Brandon Triplett; Paul G Thomas
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

2.  RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness.

Authors:  Tanya Novak; Mark W Hall; Douglas R McDonald; Margaret M Newhams; Anushay J Mistry; Angela Panoskaltsis-Mortari; Peter M Mourani; Laura L Loftis; Scott L Weiss; Keiko M Tarquinio; Barry Markovitz; Mary E Hartman; Adam Schwarz; Wolfgang G Junger; Adrienne G Randolph
Journal:  J Allergy Clin Immunol       Date:  2020-02-06       Impact factor: 10.793

3.  Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.

Authors:  Barbara Ziffels; Marco Stringhini; Philipp Probst; Tim Fugmann; Theo Sturm; Dario Neri
Journal:  Mol Cancer Ther       Date:  2019-06-18       Impact factor: 6.261

4.  New models of lipopolysaccharide-induced implantation loss reveal insights into the inflammatory response.

Authors:  Sarah Moustafa; Dana N Joseph; Robert N Taylor; Shannon Whirledge
Journal:  Am J Reprod Immunol       Date:  2019-01-28       Impact factor: 3.886

5.  Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis.

Authors:  Rafaela Pires da Silva; João Ismael Budelon Gonçalves; Rafael Fernandes Zanin; Felipe Barreto Schuch; Ana Paula Duarte de Souza
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 6.  Potential role of IFN-α in COVID-19 patients and its underlying treatment options.

Authors:  Lei Yang; Jianhui Wang; Pei Hui; Timur O Yarovinsky; Saiaditya Badeti; Kien Pham; Chen Liu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-05       Impact factor: 4.813

7.  Cytokine-specific autoantibodies shape the gut microbiome in autoimmune polyendocrine syndrome type 1.

Authors:  Anders Ø Petersen; Martta Jokinen; Damian R Plichta; Gerhard Liebisch; Wolfram Gronwald; Katja Dettmer; Peter J Oefner; Hera Vlamakis; Daniel C Chung; Annamari Ranki; Ramnik J Xavier
Journal:  J Allergy Clin Immunol       Date:  2021-04-02       Impact factor: 14.290

8.  Internal driving factors leading to extrahepatic manifestation of the hepatitis C virus infection.

Authors:  Zhou-Yi Wu; Jian-Rui Li; Meng-Hao Huang; Jun-Jun Cheng; Hu Li; Jin-Hua Chen; Xiao-Qin Lv; Zong-Gen Peng; Jian-Dong Jiang
Journal:  Int J Mol Med       Date:  2017-10-05       Impact factor: 4.101

9.  High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.

Authors:  Elita Yuliantie; Xinchuan Dai; Dehua Yang; Peter J Crack; Ming-Wei Wang
Journal:  Acta Pharm Sin B       Date:  2018-07-10       Impact factor: 11.413

Review 10.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy.

Authors:  Marion Grard; Camille Chatelain; Tiphaine Delaunay; Elvire Pons-Tostivint; Jaafar Bennouna; Jean-François Fonteneau
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.